Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
Retrieved on:
Thursday, March 28, 2024
MEG, Development, Psychiatry, Veteran, Physician, Post-traumatic stress disorder, NSI, Analysis of variance, Patient, UC, RPQ, Jesse Russell, Radiology, Human services, PCS, Concussion, Trial of the century, University, McGill Pain Questionnaire, Brain damage, Pain, ANOVA, Vaccine, PTSD, MPQ, Medical imaging
HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the positive results of a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, and is further detailed in an abstract co-authored by the United States Department of Veterans Affairs (VA) San Diego Healthcare System, and the Radiology, Psychiatry and Neurosciences Departments of UC San Deigo.
Key Points:
- mTBI is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public.
- However, the underlying pathophysiology is not completely understood, and there are few effective treatments for post-concussive symptoms (PCS).
- The study was conducted as a randomized, double-blind, placebo-controlled clinical trial over an eight-week period, with two groups being examined: an active tACS group and a sham tACS group.
- Mark White, CEO of Nexalin Technology, stated, "We are encouraged by the results of the clinical study, reinforcing the significant reduction in pain and other persistent symptoms of mild traumatic brain injury among veteran patients.